Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) announced this week that the previously planned acquisition of public company MedReleaf Corp. (TSX: LEAF) has been made official. This merger concludes one of the largest transactions completed by two public companies involved in the cannabis sector.
Under the terms of the agreement between the two companies, shareholders of MedReleaf will receive 3.575 common shares of Aurora for each MedReleaf common share held.
By completing this acquisition, Aurora Cannabis will become capable of delivering an output of more than 570,000 kg of cannabis for the medicinal and recreational cannabis markets in Canada, as well as, to the company’s already established operations in Europe. The integration of MedReleaf also means that Aurora Cannabis now owns two GMP certified facilities.
Based upon advanced analytical data and market research Aurora will now launch its portfolio of premium wellness brands such as San Rafael ’71, Woodstock, and AltaVie. Aurora’s management team believes that their operational cost should fall below $1.00 per gram of dried cannabis with the addition of MedReleaf’s R&D team, management team, and infrastructure.
Terry Booth, CEO of Aurora Cannabis, gave this statement in the press release:
“The combination of MedReleaf and Aurora creates a well capitalized company positioned exceptionally well to generate further shareholder value, driven by the low-cost production of high-quality cannabis products. We will be applying our proven integration methodology, and will continue to execute to the Aurora Standard in capitalizing on the significant opportunities in the domestic and global cannabis industry.”
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…